Press Release Source: eGene Inc.
eGene is Seeking Partners for Its Business of DNA Samples Collection in Airport Terminals
Thursday April 27, 12:40 pm ET
IRVINE, Calif.--(BUSINESS WIRE)--April 27, 2006--eGene Inc. (OTCBB:EGEI - News), a leading biotechnology company, announced that it is looking for global business partners in the DNA sample collection in airport terminals.
ADVERTISEMENT
The company's leading product, the compact and automated digital genetic analyzer, HDA-GT12(TM), is already achieving rapid penetration and acceptance in the current genetic research and testing market. Acting CEO of eGene, Dr. Ming Liu, said, "The DNA samples collection combines both the informative and instrumental aspects of DNA analysis, which is an integral part of our business approach."
eGene was awarded a U.S. patent (6,645,718) titled, "DNA sample collection for identification." The patent describes a process of collecting DNA samples for identification purposes in the event of a cataclysmic accident. This is a new, low-cost way to benefit air travel passengers and their families.
For example, in the last decade, hundreds of plane crash victims have remained unidentified because of incomplete information. Dr. Liu believes that airline passengers can take advantage of the company's patented identification technology and process in combination with flight insurance purchases, or through the requirements of various airlines.
"Passengers can choose to temporarily store their DNA samples at an airport terminal for specific flights," Dr. Liu explained. "In the event of an accident, the stored samples can be sent to authorized DNA testing labs for faster personal identification. This benefits the victims' families, the airlines and the insurance companies by avoiding time-consuming and costly individual DNA identification work."
The company is looking for a partner to collaborate with on this venture, which it emphasizes has tremendous business potential. "Even if only 10 percent of all travelers chose to use this service, we would be collecting millions of samples daily," Dr. Liu said. "We are eagerly positioning our company to catch the wave of genetic-related business."
Interested parties can contact the company for further information.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
Contact:
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
--------------------------------------------------------------------------------
Source: eGene Inc.
